Visiongain launches report entitled Global Influen
Post# of 301275
LONDON, July 06, 2017 (GLOBE NEWSWIRE) -- Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.
The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $4.97 billion in 2017.
How this report will benefit you:
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW.
In this brand new 147 page report you will find 64 in-depth tables, charts and graphs – all unavailable elsewhere.
The report provides clear detailed insight into the global influenza market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you will stay better informed and ready to act.
Need more info?
Please email sara.peerun@visiongain.com for a free report overview. Or call me in our London office on +44 0 20 8781 6960
To see the full report table of content please click on: https://www.visiongain.com/Report/1769/Global...-2017-2027
What is the scope of this report?
Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national levels.
The study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
- Trivalent Influenza Vaccines (TIV)
- Quadrivalent Influenza Vaccines (QIV)
Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share
- Sanofi Pasteur
- GSK
- Seqirus
- AstraZeneca
- Protein Science Corporation
- Others
From 2017, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potential. Our report analyses the vaccines in research and development and assesses their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal influenza vaccines in development
• Universal influenza vaccines in development
The report includes forecasts and analysis of pipeline developments for the following specific vaccines:
- Fluzone / VaxiGrip
- Seqirus
- Fluarix / FluLaval
- FluMist / Fluenz
- FluBlok
- Other
The study shows you prospects for drug sales in developed and developing regions. There see individual revenue forecasts to 2027 for 11 countries:
- United States
- Japan
- The EU 5 - Germany, France, United Kingdom, Italy and Spain
- Brazil, Russia, India and China
Who should read this report?
- Anyone within the influenza vaccines value chain
- Pharmaceutical companies
- Vaccine manufacturers
- Healthcare biotech companies
- Generics and biosimilar producers
- Drug delivery companies and other technology providers
- Contract/clinical research organisations (CROs)
- Pharma contract manufacturers
- Pharma/healthcare wholesale and distribution companies
- Medical device companies
- Healthcare diagnostics companies
- R&D specialists
- Business development managers
- Marketing managers
- Technologists
- Suppliers
- Investors
- Banks
- Government agencies
- Contractors
Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.
Read our report today: Global Influenza Vaccines - World Industry Market Outlook 2017-2027: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.
Avoid missing out by staying informed – get our report now.
Need more info?
Please email Sara Peerun on: sara.peerun@visiongain.com for a free report overview. Or call me in our London office on +44 0 20 8781 6960
To see the full report table of content please click on: https://www.visiongain.com/Report/1769/Global...-2017-2027
Companies Listed in this report include:
Advisory Committee for Immunization Practices Astellas Pharmaceuticals AstraZeneca Bharat Immunologicals and Biologicals Corporation Limited Binnopharm bioCSL BioManguinhos/Oswaldo Cruz Foundation BiondVax Bionor Brazilian Ministry of Health Butantan Institute Center for Biologics Evaluation and Research Centre for Disease Control and Prevention China National Biotech Group China’s National Regulatory Authority Chinese Food and Drug Administration CSL CureVac Daiichi Sankyo Dynavax Flanders Institute Food and Drug Administration FORT Fresenius Pharmaceuticals Gamma Vaccines Gavi Alliance GlaxoSmithKlein GlaxoWellcome Global Influenza Programme Grippol Health Service Bureau, Japan Immune Targeting Systems Indian Association of Paediatrics Janssen Pharmaceuticals Jenner Institute, University of Oxford Johnson & Johnson Krka Pharmaceuticals Medicago Medicare MedImmune Merck MSD Pharmaceuticals National Health Service, UK Novartis Organisation for Economic Co-operation and Development Panacea Biotech Partnership for Influenza Vaccine Introduction Petrovax Pfizer Protein Science Corporation Sanofi Pasteur Servizio Sanitario Nationale Shionogi Pharmaceuticals Sistema Unico de Saude SmithKline Beecham Takeda Pharmaceuticals Terumo Pharmaceuticals The Ministry of Health, Labour and Welfare, Japan The Scripps Research Institute Ultriks US Department of Health and Human Services VaxInnate WHO Strategic Advisory Group of Experts World Health Organization
Need more info?
Please email sara.peerun@visiongain.com for a free report overview. Or call me in our London office on +44 0 20 8781 6960
To see the full report table of content please click on: https://www.visiongain.com/Report/1769/Global...-2017-2027
(0)
(0)